aTyr Pharma (LIFE) Stock Price, News & Analysis

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.57 to $2.07
• 52-Week Range: N/A
• Volume: 269,400 shs
• Average Volume: 514,103 shs
• Market Capitalization: $131.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LIFE Stock Analysis - Frequently Asked Questions

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.11 million.

When did aTyr Pharma's stock split?

aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019.The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO).

Company Calendar

• Last Earnings: 5/02/2024
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LIFE
• CIK: 1339970
• Web: www.atyrpharma.com
• Phone: (858) 731-8389
• Fax: 858-731-8394
• Employees: 56
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.39 million
• Net Margins: N/A
• Pretax Margin: -9,172.11%
• Return on Equity: -56.92%
• Return on Assets: -43.87%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 6.07
• Quick Ratio: 6.07

Sales & Book Value

• Annual Sales: $350 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 69,010,000
• Free Float: 66,458,000
• Market Cap: $131.12 million
• Optionable: Optionable
• Beta: 1.19